 |
|
|
| |
CRV431 and CMX157 (TXL; tenofovir exalidex):
Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
R. FOSTER1, D. TREPANIER1, D. URE1 , J. GREYTOK1, J.L. KULP2, P. GALLAY3
1 Contravir Pharmaceuticals Inc, Edison, New Jersey, USA and Edmonton, Alberta, Canada
2 Baruch S. Blumberg Institute, Doylestown, Pennsylvania, USA 3 The Scripps Research Institute, La Jolla, California, USA
|
| |
|
|
|
|
|
